Zur Therapie der chronischen Bronchitis
Journal/Book: Therapiewoche. 1987; 37: 2803-2809.
Abstract: The efficiency and tolerance of Asthmakhell tincture for peroral use, a phytotherapeuticum that supports expectoration and shows spasmolytic effects was compared in a randomised, multicentric double-blind study with theophylline-solution in cases of chronical bronchitis. There were 16 patients in both therapeutic groups. In each group 8 female and 8 male patients with an average age of 51 to 55 years suffered between 33 to 44 months from their disease. After a therapy of 4 weeks the Asthmakhell group showed an average increase of their vital capacity from 3.06 to 3.15 ltrs., in the control group the rate changed from 2.79 to 3.03 ltrs. The treatment with Asthmakhell improved the FEV1 (forced expiratory volume per sec.) from 72.2 to 78.6 p. c. The theophylline treatment resulted in an increase of the FEV, from 61.0 to 68.8 p.c. The auscultatory breathing sounds of 11 patients improved under Asthmakhell therapy, whereas this was the case with 8 patients of the theophylline group. Cough was reduced by Asthmakhell in 14 cases, in 8 cases by theophylline. In nearly all cases tolerance was considered as good, only in one case the treatment had to be stopped because of side effects. Compared with theophylline-solution Asthmakhell shows similar clinical results in cases of less complicated chronic bronchitis.